肺癌的分子病理诊断现状及研究进展
|
摘要
随着医学技术的快速发展及人们的诊疗意识的普及,人们对临床疾病诊断与治疗的关注度越来越高。肺癌作为全球范围内发病率和死亡率较高的恶性肿瘤之一,由于肺癌病理类型分为鳞癌、腺癌、小细胞肺癌等几种病理类型,病理类型在一定程度上对诊疗方案的选择具有决定性作用。目前,病理诊断已经发展至分子病理,即是利用分子生物学技术检测和判断细胞组织的分子遗传上是否存在变异,从而更有好的指导临床诊疗。笔者就分子病理在肺癌领域诊断的应用现状和研究进展做一综述。
With the rapid development of medical technology and the popularity of people's diagnosis and treatment, people pay more and more attention to the diagnosis and treatment of clinical diseases. Because the pathological types of lung cancer are divided into squamous cell carcinoma, adenocarcinoma, small cell lung cancer and other pathological types, the pathological type plays a decisive role in the selection of diagnosis and treatment options to a certain extent. At present, pathological diagnosis has been developed to molecular pathology, that is, the use of molecular biology techniques to detect and determine the molecular genetic variation of cell tissue, thus better guiding clinical diagnosis and treatment. The author reviews the application status and research progress of molecular pathology in the diagnosis of lung cancer.
With the rapid development of medical technology and the popularity of people's diagnosis and treatment, people pay more and more attention to the diagnosis and treatment of clinical diseases. Because the pathological types of lung cancer are divided into squamous cell carcinoma, adenocarcinoma, small cell lung cancer and other pathological types, the pathological type plays a decisive role in the selection of diagnosis and treatment options to a certain extent. At present, pathological diagnosis has been developed to molecular pathology, that is, the use of molecular biology techniques to detect and determine the molecular genetic variation of cell tissue, thus better guiding clinical diagnosis and treatment. The author reviews the application status and research progress of molecular pathology in the diagnosis of lung cancer.
引文
[1]郑杰.不同手术方式对早期非小细胞肺癌患者的近远期疗效观察[J].现代诊断与治疗,2016,27(20):3935-3936.
[2]李寅.分子病理诊断的现状与思考[J].世界最新医学信息文摘,2018,18(65):39-41.
[3]张萍,武晓楠,聂鑫,等.晚期肺腺癌EGFR基因突变及临床特征分析[J].实用肿瘤杂志,2018,33(02):150-153.
[4]中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟.晚期非小细胞肺癌分子靶向治疗专家共识(2013版)[J].中华结核和呼吸杂志,2014,37(3):177-183.
[5]Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma.[J].The Journal of Evidence-Based Medicine,2009,361(10):947.
[6]Goto K,Ichinose Y,Ohe Y,et al.Epidermal growth factor receptormutation status in circulating free DNA in serum:from IPASS,a phaseIII study of gefitinib or carboplatin/paclitaxel in non-small cell lungcancer[J].J Thorac Oncol,2012,7(1):115-121.
[7]Kai G,Zhang Z P,Lu H,et al.Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer[J].Oncotargets&Therapy,2015,8(default):3289-3296.
[8]Yung TK,Chan KC,Mok TS,et al.Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients[J].Clin Cancer Res,2009,15(6):2076-2084.
[9]Oxnard GR,Paweletz CP,Kuang Y,et al.Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cellfree plasma DNA[J].Clin Cancer Res,2014,20(6):1698-1705.
[10]Couraud S,Vaca-Paniagua F,Villar S,et al.Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers:a proof-of-concept study from BioCAST/IFCT-1002[J].Clin Cancer Res,2014,20(17):4613-4624.
[11]郭海华,郭婷,黄立军,等.免疫组化法检测恶性胸腔积液脱落细胞EGFR突变状态[J].临床与病理杂志,2015,35(7):1313-1317.
[2]李寅.分子病理诊断的现状与思考[J].世界最新医学信息文摘,2018,18(65):39-41.
[3]张萍,武晓楠,聂鑫,等.晚期肺腺癌EGFR基因突变及临床特征分析[J].实用肿瘤杂志,2018,33(02):150-153.
[4]中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟.晚期非小细胞肺癌分子靶向治疗专家共识(2013版)[J].中华结核和呼吸杂志,2014,37(3):177-183.
[5]Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma.[J].The Journal of Evidence-Based Medicine,2009,361(10):947.
[6]Goto K,Ichinose Y,Ohe Y,et al.Epidermal growth factor receptormutation status in circulating free DNA in serum:from IPASS,a phaseIII study of gefitinib or carboplatin/paclitaxel in non-small cell lungcancer[J].J Thorac Oncol,2012,7(1):115-121.
[7]Kai G,Zhang Z P,Lu H,et al.Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer[J].Oncotargets&Therapy,2015,8(default):3289-3296.
[8]Yung TK,Chan KC,Mok TS,et al.Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients[J].Clin Cancer Res,2009,15(6):2076-2084.
[9]Oxnard GR,Paweletz CP,Kuang Y,et al.Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cellfree plasma DNA[J].Clin Cancer Res,2014,20(6):1698-1705.
[10]Couraud S,Vaca-Paniagua F,Villar S,et al.Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers:a proof-of-concept study from BioCAST/IFCT-1002[J].Clin Cancer Res,2014,20(17):4613-4624.
[11]郭海华,郭婷,黄立军,等.免疫组化法检测恶性胸腔积液脱落细胞EGFR突变状态[J].临床与病理杂志,2015,35(7):1313-1317.